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Abstract. The tumor suppressor gene TP53 is implicated in the exons, of which the first one is noncoding. This
regulation of normal cell growth and division, DNA repair and phosphoprotein, with a molecular weight of 53 kDa, can act
apoptosis. Mutations in this gene usually give rise to a as a transcription factor. TP53 has been implicated in the
conformationally altered protein which is stably expressed at regulation of normal cell growth and division, DNA repair
high levels. We have studied TP53 protein accumulation in and apoptosis. Inactivation of TP53 is one of the most
routinely prepared cytosols from 1491 human primary breast common molecular genetic events described so far in the
cancer specimens (median follow-up of patients alive, 66 development of cancer. This inactivation may occur by
months), using a quantitative luminometric immunoassay binding to certain viral transforming proteins, to the cellular 
(LIA). The TP53-LIA values varied between 0 and 153.53 oncogene product of the murine double minute 2 protein or 
(median 0.20 ng/mg protein). Median TP53 levels were to heat shock protein 70, which all neutralize its activity.
significantly higher in ER- and PgR-negative tumors. In Cox Another way to inactivate TP53 gene function is through gene
univariate regression analysis, when analyzed as a continuous mutation (reviewed by Greenblatt et al) (9). These mutations
variable, increasing TP53 levels were related with a poor relapse- are mostly missense, resulting in a stably expressed conforma-
free survival (p<0.01). In multivariate analysis for relapse-free tionally altered protein which is detectable by immuno-
survival, including age, menopausal status, tumor size, nodal histochemical, ELISA or Western blotting techniques (3,12)
status and steroid hormone receptor status, TP53 accumulation, To study its prognostic significance, we examined TP53
when analyzed as a dichotomized variable, was an independent protein accumulation in primary breast tumor cytosols,
factor for predicting the rate of relapse with a relative relapse rate routinely prepared for steroid hormone receptor analysis,
(95% confidence limits) of 1.39 (1.19-1.63). In conclusion, the using a quantitative luminometric immunoassay (LIA). TP53
LIA for the TP53 protein can easily be performed on cytosols protein accumulation was related to patient and tumor
routinely prepared for steroid hormone receptor analysis, it is a characteristics, and with a clinical outcome of breast cancer
quantitative assay, and it may be useful in establishing the patients. 
relation of TP53 accumulation and breast cancer prognosis.
Patients and Methods
The human tumor suppressor gene TP53 is located on 
chromosome band 17pl3.1 and consists of eleven separate In this study, primary breast tumor specimens, used for routine steroid
hormone receptor analysis, from 1491 patients with known follow-up 
were included. All patients had primary invasive breast cancer with no 
signs of distant metastasis at time of surgery. The median age of the 
patients was 56 years (range: 24-89, mean 56 years). Forty-one percent of 
the patients were premenopausal, 59% postmenopausal; 46% had no
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involved lymph-nodes, and 42% of the tumors were smaller than 2cm 
(Tl). Of these patients 23% received adjuvant treatment, 
follow-up of patients ; alive was 66 months. During follow-up, 686 
patients experienced a'relapse and 505 patients died.
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Table I. Between assay variation ofTP53 (n=15 assays).
Sample Mean MIN MAX S.D. %C.V.
Control
“low” 0.21 0.18 0.23 0.02 9.5
Control
“high” 8.44 7.49 9.47 0.47 5.6
O
o
i-H
Sample
“reference” 2.96 2.49 3.39 0.27 9.1
D
Sample
“cytosol pool” 0.89 0.78 1.06 0.10 11.2
p53 protein (ng/ml)
stored in liquid nitrogen. The samples were pulverized in the frozen 
state and homogenized in a phosphate buffer according to procedures 
recommended by the EORTC for the preparation of cytosols for ER
and PgR measurement (EORTC Breast Cancer Cooperative Group Figure X.A representative standard curve for TP53 protein analysis. 
1980) (7). ER and PgR were measured by ligand binding assay or with 
enzyme immunoassays (8).
Luminometric immunoassay. The TP53 protein levels of the breast tumor
cytosols were measured using a quantitative luminometric immunoassay Table II. Multivariate analysis o f relapse-free survival in 1479patients. 
(LIA; AB Sangtec Medical, Bromma, Sweden) as described by Borg et 
al. (4). The LIA is based on a combination of two monoclonal 
antibodies, pAB1801 and D01, which detect both wild-type and mutant 
TP53 protein ndwich-type assay. The monoclonal antibody pAB1801, 
which is immobilized onto a solid phase (tube), is used for catching .
Monoclonal antibody DO 1, labeled with a chemiluminescent compound 
(amino-butyl-ethyl-isoluminol: ABEI), is used for detection. The 
immunoassay was performed by incubating either 100 |xl of TP53 
standard (range: 0-80 ng/ml), controls or tumor cytosols, together with 
100 |il of the ABEI-conjugate in pre-coated tubes. After incubation for 
18 hours at room temperature, unbound reagents were removed by 
washing the tubes three times with 2 ml 0.9% sodium chloride. The
chemiluminescent reaction was initiated by the sequential addition of 
300 (J.1 alkaline hydrogen peroxide and 300 1^ catalyst (microperoxidase) 
solution, immediately followed by measurement of the chemilumi­
nescent counts in a luminometer. The TP53 protein contents of the 
samples were determined from the standard curve, plotting the 
chemiluminescent response (in relative light units: RLU) against the 
standard concentrations of the TP53 protein. A representative standard 
curve is shown in Figure 1. The detection limit is approximately 0.01 ng 
TP53 per ml sample, The concentration of TP53 protein in the tumor 
cytosols is expressed as ng/mg cytosolic protein (the protein 
concentration of all samples was brought to 0.5 mg/ml cytosol, with kit 
diluent buffer).
Variable RHR 95% CL P
Age and menopausal status <0.001
a
Age premenopausal 0.69 0.59-0.82
Age postmenopausal 0.95 0.83-1.08
Post vs. premenopausal 1.31
*
1.05 -1.63
Tumor size (= < 2  vs. >2 cm) 0.68 0.57-0.81 <0.001
Nodal status <0.001
1-3 vs. 0 1.67 1.37-2.04
>3 vs. 0 3.42 2.82-4.14
TP53 (high vs. low) 1.39 1.19-1.63 <0.001
Results and Discussion
Statistical analysis. The relations between TP53 protein levels and 
patient- and tumor characteristics were studied with non-parametric 
tests: the Wilcoxon test (menopausal status, tumor size, ER, PgR), the
The TP53-LIA was performed on 1491 primary breast tumor 
cytosols. Fifteen separate experiments were required to 
obtain all the results. In each experiment the kit controls
Kruskall-Wallis test including a Wilcoxon-type test for trend for ordered (“low” and “high”), a “reference” preparation and a tumor
variables (nodal status) and additionally the Spearman Rank correlation “cytosol pool” were included. The assays were highly
for continuous variables. Isotonic regression analysis was performed in reproducible and the between-assay variation ranged from
order to determine the cut-off level for TP53 accumulation (2). c , • -x, , , T\  r^u T,nco * • i„ , r . , , ...... , . „ , , . v ,  5.6% and 11.2% (shown m Table I). The TP53 protein valuesRelapse-free survival probabilities were calculated by the actuarial v ; i , r
method of Kaplan and Meier (10). The Cox proportional hazard model the 1491 breast tumor cytosols ranged between 0 and
was used for uni- and multivariate survival analyses. 153.53 ng/mg cytosolic protein (median 0.20 ng/mg protein).
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Figure 2. Relationship of TP53 with patient and tumor characteristics.
TP53 accumulation related with patient and tumor and In univariate analysis TP53 protein accumulation was
characteristics. With regard to patient- and tumor significantly associated with an increased relapse rate. In a
characteristics there were no significant relationships between multivariate analysis for relapse free survival, including age,
TP53 protein levels and menopausal status, nodal status or menopausal status, tumor size, nodal status and steroid
tumor size (Figure 2). The Spearman rank correlation hormone receptor status, TP53 protein accumulation
coefficients between the levels of TP53 with ER and PgR (analyzed as a dichotomized variable) was an independent
were -0.06 and -0.04, respectively (not significant). However, factor for predicting the rate of relapse (Table II). The RHR,
in ER-negative and PgR-negative tumors, TP53 protein levels relative hazard rate, (with 95% CL, confidence limits) was
were significantly higher when compared to ER-positive and 1.39 (1.19-1.63). This study supplements those of Thor et al
PgR-positive tumors (P=0.0001 and P=0.0002 respectively, (11), Andersen et al and Elledge et al (6), who also observed a
shown in Figure 2). This is in agreement with studies by relation between immunohistochemically assessed TP53
others (reviewed by Elledge and Allred, 1994). protein accumulation and shorter relapse-free survival, and 
confirms that of Borg et al (4) who employed the same assay
TP53 accumulation and prognosis. Isotonic regression analysis as we used in this study.
was applied with relapse-free survival as the end point for all In conclusion, the LIA for the TP53 protein can easily be
1491 tumor samples, and 0.38 ng/mg protein was chosen as performed on cytosols prepared for steroid
cut-off point to discriminate between high/accumulated TP53 hormone receptor analysis, it is a quantitative assay, and it
protein (34%) and low TP53 protein levels (66%). This may be useful in establishing the relation of TP53
prevalence is comparable with the TP53 protein accumulation accumulation and breast cancer prognosis. However, of all
of 30% and 28%, observed in smaller series of breast tumors mutations studied at the TP53 locus in breast cancer, about
studied by Borg et al (4) and us (de Witte et al (5) 16% are deletions, insertions or stopcodons, resulting in a
respectively. Moreover, this is well in line with the percentage deletion or truncation of the protein in the cell (Greenblatt et
of TP53 gene alterations or protein overexpression, observed al (9). Unfortunately the latter alterations are not revealed
in 14-52% of 3000 human breast tumors using molecular or with immunological techniques. Using Kaplan-Meier analyses
immunological techniques (reviewed by Elledge and Allred, we observed that both subsets of patients with either TP53
1994). protein accumulation or very low expression do worse (not
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shown). This implies that more studies will be needed to 
define cut-off points for the subset with veiy low expression.
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